MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways


Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast cancers following failure of previous tamoxifen or aromatase inhibitor therapies. However, after prolonged fulvestrant therapy, acquired resistance eventually occurs in the majority of breast cancer patients, due to poorly understood… (More)
DOI: 10.1038/onc.2010.487


9 Figures and Tables